Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cyclofem/Cyclo-Provera: emerging countries' perspective

J Garza-Flores1

  • 1Department of Reproductive Biology, National Institute of Nutrition, Salvador Zubirán, México City, Mexico.

International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics
|November 7, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mesigyna once-a-month combined injectable contraceptive: experience in Latin America.

Contraception·2000
Same author

Reversible contraception: issues faced by emerging countries.

International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics·1998
Same author

Introduction of cyclofem once-a-month injectable contraceptive in Mexico.

Contraception·1998
Same author

A multicenter comparative study on the efficacy, safety, and acceptability of the contraceptive subdermal implants Norplant and Norplant-II.

Contraception·1997
Same author

Ability of an anti-luteinizing hormone-releasing hormone vaccine to inhibit gonadotropins in postmenopausal women.

Fertility and sterility·1997
Same author

Review of ovulation return upon discontinuation of once-a-month injectable contraceptives.

Contraception·1994
Same journal

Response: A comparison in maternal and neonatal outcomes between mild fundal pressure and vacuum extraction for shortening the second stage of labor-Fundal pressure maneuvers are not created equal.

International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics·2026
Same journal

Comparison of outpatient versus inpatient management after early stabilization in preterm prelabor rupture of membranes <34 weeks: Maternal safety, latency, and neonatal outcomes.

International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics·2026
Same journal

Flat glucose response curve during pregnancy and perinatal outcomes: A systematic review and meta-analysis.

International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics·2026
Same journal

Preserved large elastic arterial stiffness and impaired conduit artery endothelial function in patients with endometriosis receiving progestin therapy: A cross-sectional observational study.

International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics·2026
Same journal

Development and validation of machine learning-based model for macrosomia and spontaneous preterm birth: A retrospective cohort study.

International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics·2026
Same journal

Letter to the editor: Anovulatory bleeding and the spectrum of bleeding disorders: Understanding heavy menstrual bleeding in adolescents.

International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics·2026
See all related articles

Medroxyprogesterone acetate/estradiol cypionate (MPA/E2C) is a highly effective injectable contraceptive with a pregnancy rate under 1%. Service delivery, not the method itself, significantly impacts discontinuation rates.

Area of Science:

  • Reproductive Health
  • Contraception
  • Endocrinology

Background:

  • Medroxyprogesterone acetate and estradiol cypionate (MPA/E2C) is an injectable contraceptive.
  • Previous studies indicate its high use-effectiveness in preventing pregnancy.

Purpose of the Study:

  • To evaluate the effectiveness and discontinuation rates of MPA/E2C.
  • To assess the role of service delivery in the continued use of this contraceptive method.

Main Methods:

  • Analysis of life-table discontinuation rates from trials.
  • Review of pregnancy rates in routine service delivery conditions.

Main Results:

  • MPA/E2C demonstrates a pregnancy rate below 1%.
  • One-year discontinuation rates varied widely (33.5%–71.8%).

Related Experiment Videos

  • Only one-third of discontinuations were method-related; service delivery issues were more significant.

    • Conclusions:

    • MPA/E2C is a highly effective contraceptive option.
    • Improving service delivery is crucial for sustained use of MPA/E2C.
    • MPA/E2C has been approved and integrated into family planning programs globally.